James L Chen, MD
Academic Title: Associate Professor in the College of Medicine
Research Program: Translational Therapeutics
About Me
More info forI’m a medical oncologist and researcher treating patients with sarcomas as well as poorly classified and difficult-to-treat tumors. My primary role is to treat the complete patient, not just the cancer. I am also medical director of Clinical and Research Informatics for the James Cancer Hospital to help facilitate and improve cancer research. I am committed to understanding our patients’ entire health backgrounds, the biology of their tumors and separate health factors so we can customize a sophisticated, targeted treatment regimen that is specific for each patient. I was rated in the top 10 percent of physicians in the nation for patient satisfaction for multiple years. I serve as an associate professor in the Departments of Internal Medicine and Biomedical Informatics at The Ohio State University As a researcher with a background in developing sophisticated software to analyze cancer data, I’m honored to work at a world-class, comprehensive cancer center where treatment is a collaborative effort of accomplished, accessible, compassionate professionals who extend beyond measures to provide first-class patient care. Research is critical to treating these types of cancers that are often poorly understood. As a member of the Translational Therapeutics Program at the OSUCCC – James, my research focus is on using computers to better understand complex gene data in cancer. My lab is applying a matching algorithm that uses genomic predictors to identify sarcoma patients who are sensitive to different treatments. My work has been published in more than 50 articles in peer-reviewed journals such as Science Translational Research, Journal of Biomedical Informatics, Clinical Cancer Research, Journal of Surgical Oncology and Journal of the American Medical Informatics Association. I also hold multiple national and international leadership roles in organizations such as the ALLIANCE National Clinical Trials Network and the American Society of Clinical Oncology.
Clinical Expertise
More info for- Sarcoma
- Urologic Cancers
- Soft Tissue Cancers
- Peritoneal Cancers
- Osteosarcoma
Research Interests
More info for- Sarcoma
- Prostatic Neoplasms
- Neoplasms
- Carcinoma, Renal Cell
- Hemorrhage
Where I See Patients
More info forThe Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
460 W. 10th Ave. Columbus, Ohio 43210 800-293-5066 Location InformationEducation & Training
More info forInternship - Internal Medicine
- MedStar Georgetown University Hospital
3800 Reservoir Rd NW, Washington, DC
Residency - Internal Medicine
- MedStar Georgetown University Hospital
3800 Reservoir Rd NW, Washington, DC
Medical School
- Rutgers New Jersey Medical School
185 S Orange Ave, Newark, NJ
Fellowship - Hematology & Oncology
- University of Chicago School of Medicine
5841 S Maryland Ave, Chicago, IL
Fellowship - Medical Oncology
- University of Chicago School of Medicine
5841 S Maryland Ave, Chicago, IL
- MedStar Georgetown University Hospital
Academic Office & Contact Information
More info forAcademic Office:
Lincoln Tower
1800 Cannon Dr
Columbus, Ohio 43210Phone:
614-688-6600Email:
chen.3843@osu.eduReviews
More info forPatient Satisfaction Review
The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our
Patient Satisfaction Survey page The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.
Videos
More info forPublications
More info forSeptember 28, 2024A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses.
Seligson ND, Chen JL, Goodrich AC, Van Tine BA, Campbell JD, Richards AL, Antonescu CR, Liebner DA, Milhem MM, Streicher H, Tap WD, Schwartz GK, George S, D'Angelo SP
J Immunother Cancer
July 17, 2024Use of neoadjuvant paclitaxel in breast angiosarcoma-Impact on surgical resection and response rates.
Selby LV, Clark E, Chen JL, Tinoco G, Beane JD, Pollock RE, Liebner D, Grignol VP
J Surg Oncol
February 16, 2024Association Between Neighborhood Opportunity, Allostatic Load, and All-Cause Mortality in Patients With Breast Cancer.
Chen JC, Elsaid MI, Handley D, Plascak JJ, Andersen BL, Carson WE, Pawlik TM, Fareed N, Obeng-Gyasi S
J Clin Oncol
January 25, 2024ASO Visual Abstract: Adjuvant Palbociclib May be Associated with Delayed Recurrence in Completely Resected Retroperitoneal Liposarcoma: Results of a Single-Institution Retrospective Cohort Study.
Selby LV, Clark EC, Liebner DA, Chen JL, Tinoco G, Bashian E, Beane JD, Pollock RE, Grignol VP
Ann Surg Oncol
October 10, 2023The T Cell Immunoscore as a Reference for Biomarker Development Utilizing Real-World Data from Patients with Advanced Malignancies Treated with Immune Checkpoint Inhibitors.
Eljilany I, Saghand PG, Chen J, Ratan A, McCarter M, Carpten J, Colman H, Ikeguchi AP, Puzanov I, Arnold S, Churchman M, Hwu P, Conejo-Garcia J, Dalton WS, Weiner GJ, El Naqa IM, Tarhini AA
Cancers (Basel)
October 3, 2023Gene partners of the EWSR1 fusion may represent molecularly distinct entities.
Walker V, Jin DX, Millis SZ, Nasri E, Corao-Uribe DA, Tan AC, Fridley BL, Chen JL, Seligson ND
Transl Oncol
September 7, 2023Atezolizumab for Advanced Alveolar Soft Part Sarcoma.
Chen AP, Sharon E, O'Sullivan-Coyne G, Moore N, Foster JC, Hu JS, Van Tine BA, Conley AP, Read WL, Riedel RF, Burgess MA, Glod J, Davis EJ, Merriam P, Naqash AR, Fino KK, Miller BL, Wilsker DF, Begum A, Ferry-Galow KV, Deshpande HA, Schwartz GK, Ladle BH, Okuno SH, Beck JC, Chen JL, Takebe N, Fogli LK, Rosenberger CL, Parchment RE, Doroshow JH
N Engl J Med
June 17, 2023Adjuvant Palbociclib May be Associated with Delayed Recurrence in Completely Resected Retroperitoneal Liposarcoma: Results of a Single-Institution Retrospective Cohort Study.
Selby LV, Clark EC, Liebner DA, Chen JL, Tinoco G, Bashian E, Beane JD, Pollock RE, Grignol VP
Ann Surg Oncol
April 7, 2023Clinical markers of immunotherapy outcomes in advanced sarcoma.
Husain M, Quiroga D, Kim HG, Lenobel S, Xu M, Iwenofu H, Chen JL, Verschraegen C, Liebner D, Tinoco G
BMC Cancer
September 1, 2022An Informatics Bridge to Improve the Design and Efficiency of Phase I Clinical Trials for Anticancer Drug Combinations.
Wang L, Wei L, Zhang S, Cheng L, Shendre A, Carson W, Chen JL, Owen D, Gregory M, Li L
Cancer Res Commun
April 25, 2022Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomas.
Seligson ND, Tang J, Jin DX, Bennett MP, Elvin JA, Graim K, Hays JL, Millis SZ, Miles WO, Chen JL
NPJ Precis Oncol
April 8, 2022Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.
Gounder MM, Razak AA, Somaiah N, Chawla S, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Riedel RF, Stacchiotti S, Loggers ET, Ganjoo KN, Le Cesne A, Italiano A, Garcia Del Muro X, Burgess M, Piperno-Neumann S, Ryan C, Mulcahy MF, Forscher C, Penel N, Okuno S, Elias A, Hartner L, Philip T, Alcindor T, Kasper B, Reichardt P, Lapeire L, Blay JY, Chevreau C, Valverde Morales CM, Schwartz GK, Chen JL, Deshpande H, Davis EJ, Nicholas G, Gröschel S, Hatcher H, Duffaud F, Herráez AC, Beveridge RD, Badalamenti G, Eriksson M, Meyer C, von Mehren M, Van Tine BA, Götze K, Mazzeo F, Yakobson A, Zick A, Lee A, Gonzalez AE, Napolitano A, Dickson MA, Michel D, Meng C, Li L, Liu J, Ben-Shahar O, Van Domelen DR, Walker CJ, Chang H, Landesman Y, Shah JJ, Shacham S, Kauffman MG, Attia S
J Clin Oncol
March 1, 2022Challenges and Gaps in Clinical Trial Genomic Data Management.
Asad S, Kananen K, Mueller KR, Symmans WF, Wen Y, Perou CM, Blachly JS, Chen J, Vincent BG, Stover DG
JCO Clin Cancer Inform
February 1, 2022Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges.
Hsu JY, Seligson ND, Hays JL, Miles WO, Chen JL
JCO Precis Oncol
September 24, 2021Randomized Prospective Trial Exploring the Impact of Structured Journaling in Patients With Sarcoma on the Management of Treatment-Related Adverse Events.
Speece NJ, Xu M, Tinoco G, Liebner DA, Chen JL
JCO Oncol Pract
July 2, 2021Intersectionality and the Surgical Patient: Expanding the Surgical Disparities Framework.
Chen JC, Obeng-Gyasi S
Ann Surg
May 21, 2021Multiscale-omic assessment of EWSR1-NFATc2 fusion positive sarcomas identifies the mTOR pathway as a potential therapeutic target.
Seligson ND, Maradiaga RD, Stets CM, Katzenstein HM, Millis SZ, Rogers A, Hays JL, Chen JL
NPJ Precis Oncol
March 2, 2021Modern multimodality management of patients with caval leiomyosarcoma: New treatment paradigms and potential molecular insights.
Squires MH, Politano S, Pollock RE, Chen JL, Grignol V
J Surg Oncol
February 23, 2021Compression Induced Hepatic Injury: An Unusual Case of Abnormal Liver Function Tests.
Sobotka LA, Chen JL, Wellner MR
Clin Res Hepatol Gastroenterol
August 4, 2020MDM2-Dependent Rewiring of Metabolomic and Lipidomic Profiles in Dedifferentiated Liposarcoma Models.
Patt A, Demoret B, Stets C, Bill KL, Smith P, Vijay A, Patterson A, Hays J, Hoang M, Chen JL, Mathé EA
Cancers (Basel)
July 1, 2020Collaborative, Multidisciplinary Evaluation of Cancer Variants Through Virtual Molecular Tumor Boards Informs Local Clinical Practices.
Rao S, Pitel B, Wagner AH, Boca SM, McCoy M, King I, Gupta S, Park BH, Warner JL, Chen J, Rogan PK, Chakravarty D, Griffith M, Griffith OL, Madhavan S
JCO Clin Cancer Inform
June 5, 2020Activity of PD1 inhibitor therapy in advanced sarcoma: a single-center retrospective analysis.
Quiroga D, Liebner DA, Philippon JS, Hoffman S, Tan Y, Chen JL, Lenobel S, Wakely PE, Pollock R, Tinoco G
BMC Cancer
May 7, 2020Outcomes of neoadjuvant chemotherapy before CRS-HIPEC for patients with appendiceal cancer.
Chen JC, Beal EW, Hays J, Pawlik TM, Abdel-Misih S, Cloyd JM
J Surg Oncol
May 6, 2020Metastatic breast cancer patient perceptions of somatic tumor genomic testing.
Adams EJ, Asad S, Reinbolt R, Collier KA, Abdel-Rasoul M, Gillespie S, Chen JL, Cherian MA, Noonan AM, Sardesai S, VanDeusen J, Wesolowski R, Williams N, Shapiro CL, Macrae ER, Pilarski R, Toland AE, Senter L, Ramaswamy B, Lee CN, Lustberg MB, Stover DG
BMC Cancer
Consulting and Related Relationships
More info forAt The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Chen has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.
- MatchTx, LLC
- Tempus
Patient Comments
Dr. Chen, his P.A., and all of his staff are very professional and considerate about my complete health. Dr. Chen takes time to address all of my concerns and willing to spend time making suggestions and referrals if I need care from other professionals.
Best staff !
Truly blessed to have this facility and staff available.
Being from a small town, tha entire OSU James staff is extremely pleasant and customer centered. Thank you
Both the PA, Becky and Dr. Chen were very professional and caring. Please let them know that I appreciate the time they spent with me.
The team and DrChen are wonderful.
"OSU is leading others follow"
Could I move these scores up to 6-Excellent?! (Nope, I don't say this about many providers. I'm very picky!)
Dr Chen & his office team are the best!